This post was published on ZYX Short Sell Change Alert Consider taking profits on the last tranche from around $46 right here  $43.40- 43.65. THis will leave 20% still held.

This post was published on ZYX Short Sell Change Alert We are repeating that conservative investors should not enter this trade.  Even though the trial has failed and there is not enough life left in the patent, the disease evokes such emotion the some will continue to run up the stock.  The situation can cause big draw downs.  Therefore the trade is not suitable for those who may have difficulty handling a big draw down.

This post was published on ZYX Short Sell Change Alert Consider adding another 10% tranche in the zone of $45.90 to $46.60.

This post was published on ZYX Short Sell Change Alert The stock is likely to be very volatile, conservative investors should not enter this trade.  The results of the trial are being misinterpreted by some in the market. Here are the details. LLY announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer’s disease. However, a pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer’s disease. In

This post was published on ZYX Short Sell Change Alert Stock moved right after the post. Most fills should be $43.87. Consider adding 10% around $43.80-44.50.

This post was published on ZYX Short Sell Change Alert LLY Alzheimer drug trial has failed. Consider starting a 10% tranche right here around $42.82. More later.